| Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 … M Gao, L Duan, J Luo, L Zhang, X Lu, Y Zhang, Z Zhang, Z Tu, Y Xu, ... Journal of medicinal chemistry 56 (8), 3281-3295, 2013 | 140 | 2013 |
| Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790→ methionine790 mutant S Chang, L Zhang, S Xu, J Luo, X Lu, Z Zhang, T Xu, Y Liu, Z Tu, Y Xu, ... Journal of medicinal chemistry 55 (6), 2711-2723, 2012 | 134 | 2012 |
| Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines H Cheng, L Zhang, Y Liu, S Chen, H Cheng, X Lu, Z Zheng, GC Zhou European journal of medicinal chemistry 45 (12), 5950-5957, 2010 | 83 | 2010 |
| 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor α S Xu, X Zhuang, X Pan, Z Zhang, L Duan, Y Liu, L Zhang, X Ren, K Ding Journal of Medicinal Chemistry 56 (11), 4631-4640, 2013 | 77 | 2013 |
| Novel hybrids of (phenylsulfonyl) furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer C Han, Z Huang, C Zheng, L Wan, L Zhang, S Peng, K Ding, H Ji, J Tian, ... Journal of Medicinal Chemistry 56 (11), 4738-4748, 2013 | 76 | 2013 |
| Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant W Zhou, X Liu, Z Tu, L Zhang, X Ku, F Bai, Z Zhao, Y Xu, K Ding, H Li Journal of medicinal chemistry 56 (20), 7821-7837, 2013 | 57 | 2013 |
| Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFNβ-NIS L Zhang, MB Steele, N Jenks, J Grell, L Suksanpaisan, S Naik, ... Human Gene Therapy Clinical Development 27 (3), 111-122, 2016 | 42 | 2016 |
| Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma X Wu, M Stenson, J Abeykoon, K Nowakowski, L Zhang, J Lawson, ... Blood, The Journal of the American Society of Hematology 134 (4), 363-373, 2019 | 41 | 2019 |
| C5-substituted pyrido [2, 3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant T Xu, T Peng, X Ren, L Zhang, L Yu, J Luo, Z Zhang, Z Tu, L Tong, ... MedChemComm 6 (9), 1693-1697, 2015 | 34 | 2015 |
| Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants T Xu, L Zhang, S Xu, CY Yang, J Luo, F Ding, X Lu, Y Liu, Z Tu, S Li, D Pei, ... Angewandte Chemie 125 (32), 8545-8548, 2013 | 33 | 2013 |
| Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib H Cheng, Y Chang, L Zhang, J Luo, Z Tu, X Lu, Q Zhang, J Lu, X Ren, ... Journal of Medicinal Chemistry 57 (6), 2692-2703, 2014 | 32 | 2014 |
| Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor … S Xu, T Xu, L Zhang, Z Zhang, J Luo, Y Liu, X Lu, Z Tu, X Ren, K Ding Journal of medicinal chemistry 56 (21), 8803-8813, 2013 | 31 | 2013 |
| Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins MÁ Muñoz-Alía, RA Nace, L Zhang, SJ Russell Cell Reports Medicine 2 (4), 100225, 2021 | 29 | 2021 |
| Robust oncolytic virotherapy induces tumor lysis syndrome and associated toxicities in the MPC-11 plasmacytoma model L Zhang, MB Steele, N Jenks, J Grell, M Behrens, R Nace, S Naik, ... Molecular Therapy 24 (12), 2109-2117, 2016 | 18 | 2016 |
| Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine 790→ methionine 790 mutant S Xu, L Zhang, S Chang, J Luo, X Lu, Z Tu, Y Liu, Y Xu, X Ren, K Ding MedChemComm 3 (9), 1155-1159, 2012 | 17 | 2012 |
| Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma J Cook, KW Peng, TE Witzig, SM Broski, JC Villasboas, J Paludo, ... Blood Advances 6 (11), 3268-3279, 2022 | 14 | 2022 |
| MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum MÁ Muñoz-Alía, RA Nace, A Tischer, L Zhang, ES Bah, M Auton, ... PLoS pathogens 17 (2), e1009283, 2021 | 12 | 2021 |
| Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine KW Peng, T Carey, P Lech, R Vandergaast, MÁ Muñoz-Alía, ... Vaccine 40 (15), 2342-2351, 2022 | 8 | 2022 |
| Pyrimido [4, 5-d] pyrimidinyl compounds, pharmaceutical compositions and uses thereof K Ding, S Chang, S Xu, L Zhang, Z Tu, J Ding, M Geng, Y Chen US Patent App. 14/125,304, 2014 | 8 | 2014 |
| Dual-isotope SPECT imaging with NIS reporter gene and duramycin to visualize tumor susceptibility to oncolytic virus infection L Zhang, L Suksanpaisan, H Jiang, TR DeGrado, SJ Russell, M Zhao, ... Molecular Therapy-Oncolytics 15, 178-185, 2019 | 7 | 2019 |
Shilin Xuuniversity of michigan在 umich.edu 的电子邮件经过验证
